Clinical Trials Logo
  1. Home
  2. Rheumatic Heart Disease
  3. NCT05991219
  4. Details
NCT05991219 Clinical Trial

Screening and Secondary Prevention Rheumatic Heart Disease Study

Rheumatic Heart Disease Clinical Trial

— S2-RHD  

Official title:
Screening and Secondary Prevention Rheumatic Heart Disease

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05991219
Other study ID # IRB-32/2023
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 26, 2022
Est. completion date December 31, 2028

Study information
Verified date August 2023
Source National Institute of Cardiovascular Diseases, Pakistan
Contact Sabha Bhatti, MD
Phone +92 335 5554346
Email drsabhabhatti@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

After basic clinical screening including history and physical, Point of care ultrasound will be performed to look at Mitral, Aortic and Tricuspid Valves for regurgitation or stenosis. For patients with confirmed Rheumatic heart disease (RHD), treatment and referral depending on stage of disease. Antibiotic prescription could be shifted to community health workers delivering preventive medications via practical clinical algorithms, diagnostic tools, availability of appropriate antibiotics, and supportive supervision. Patients will have repeat imaging at 2 years and 5 years to look at the outcome of delayed progression of valve disease.

Description:

Screening for RHD should be carried out since it is a major health concern that has been shown to have a treatable and detectable latent stage that can be diagnosed using a simple sensitive test (point of care ultrasound) and early treatment (secondary prevention using antibiotic prophylaxis) can provide a better outcome (slow progression of disease) in a cost effective way. The investigators aim to study the Incidence and Prevalence of RHD in community and school settings and aim to intervene depending on the stage the disease is picked up in.

Recruitment information / eligibility
Status Recruiting
Enrollment 5000
Est. completion date December 31, 2028
Est. primary completion date December 31, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 10 Years to 30 Years
Eligibility Inclusion Criteria: - Rural communities in Sindh Exclusion Criteria: - Refused to participate in the study

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Pakistan National Institute of Cardiovascular Diseases (NICVD) Karachi Sindh

Sponsors (1)
Lead Sponsor Collaborator
National Institute of Cardiovascular Diseases, Pakistan

Country where clinical trial is conducted

Pakistan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Rheumatic heart disease Number of patients At the time of screening echocardiogram
See also
  Status Clinical Trial Phase
Completed NCT02661763 - Rheumatic Heart Disease Study in Lusaka N/A
Completed NCT02188862 - Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region N/A
Completed NCT01178710 - Effect of Simvastatin on Cardiac Function N/A
Recruiting NCT05693545 - GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial Phase 2
Terminated NCT03926156 - RIvoraxaban in Mitral Stenosis Phase 3
Not yet recruiting NCT06150274 - Comparison of Wire Assisted Percutaneous Balloon Mitral Valvulotomy With Standard Inoue Balloon Valvulotomy N/A
Recruiting NCT05783375 - Accelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda N/A
Completed NCT02474108 - Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion and Left Atrium Enlargement N/A
Recruiting NCT04556188 - The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa
Recruiting NCT03991910 - The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients Phase 3
Active, not recruiting NCT03346525 - Determining the Impact of Penicillin in Latent RHD: The GOAL Trial Phase 2
Recruiting NCT05504928 - Effectiveness of a School-centered Prevention Program on Prevalence of Latent Rheumatic Heart Disease N/A
Not yet recruiting NCT03549052 - Right Ventricular Echo Assessment in Mitral Valve Replacement
Recruiting NCT05487469 - Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass N/A
Active, not recruiting NCT05276999 - Rheumatic Heart Disease Community Streptococcal Treatment Program "RESET" N/A
Completed NCT05668611 - Train the Trainer Curriculum to Scale up AI Supported Echo for RHD Screening in a Public Health System N/A
Active, not recruiting NCT05211024 - A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)
Withdrawn NCT02832531 - INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority Phase 3
Completed NCT01794884 - Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery Phase 2
Completed NCT00264524 - DNA Typing of HLA-DR/DQ Alleles in Taiwan Chinese With Rheumatic Heart Disease N/A